Hansa Biopharma AB, which appointed a new CEO and COO earlier this year, has announced plans to restructure its organization to optimize resource allocation and improve operational efficiency. The planned restructuring would result in an approximately 20% reduction in the current workforce and would result in projected annual savings of 40-50 million Swedish krona. The restructuring is subject to negotiation with relevant trade unions.

Renée Aguiar-Lucander, CEO, Hansa Biopharma said: “This planned restructuring is a strategic decision to optimize resources and improve operational efficiency at a critical time for the organization. We anticipate this will lead to cost savings as well as increased efficiency, transparency and accountability throughout the organization. We are confident that these changes are necessary and will position us to more effectively deliver value to shareholders and patients.”

As part of the restructuring, Hansa will notify the Swedish Public Employment Service and seek consultations with the trade unions regarding the reorganization. Decisions regarding employee reductions will take place after the change consultations have been concluded, according to local regulations.